Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This company is the real deal Holyfield!!!
NVLX Mainstream Investors Finally Starting to Eye Green Rush: http://mmjbusinessdaily.com/week-in-review-mainstream-investors-starting-to-eye-green-rush/
CNN Article with Nuvilex's Dr. Mark Rabe: http://www.cnn.com/2014/03/07/health/cannabis-pain/
Hmm Why would NVLX pay this 2 months early? Seems like a big hint that something is coming related to Diabetes... could they be starting trials?
So you were paid to post on ORFG ???
Feel bad for the weak hands yesterday!! This one is a gold mine!!
As far as the company replying to this article, companies can’t spend all day, every day refuting half-truths because traders get scared away; otherwise, they’d post these hit pieces even more to keep the company busy with refuting them instead of its actual work. If you know your investment, you can’t get scared off by Shorts.
You notice the article started out with and mostly discussed marijuana and didn’t touch on the company’s REAL WORK, Cell in a Box? That is done purposely. It’s like if an article came out about Apple and didn’t mention the iPhone or iPad. They don’t want to discuss Cell in a Box, the Phase III clinical trials, or the $27 million funding the company just received because the article is supposed to generate fear, and those things are positive and would send a reader away to go research those items and possibly invest… they want selling not buying.
The article was filled with a bunch of half-truths that if peeled back could easily be refuted. It discussed the company not making revenue… well, it’s an R&D Biotech, so of course they have no revenue yet. Biotech’s are often invested in and priced based on their drug or treatment’s potential in the market upon FDA approval. The article said they promote their company… every company promotes itself in one way or the other. Depending on how much money the company has… decides what method of promotion they use. But, with that promotion, the company is likely trying to attract funding… which they got from Lincoln Park Capital… so it likely worked. They are also trying to attract big pharmaceutical and biotech firms for buy-out or collaboration opportunities, and they are also educating the pancreatic cancer and diabetes communities about a potential new therapy coming their way from Nuvilex.
So, to end this rant, the company can’t sit around and defend every single half-truth to make investors feel all warm and fuzzy. It’s like politics… one candidate states a half-truth or fabricates a complete lie in an attempt to keep his opponent on defense instead of reaching out to new voters. NVLX is doing all the right things in my opinion and I believe it’s just a matter of time before the author of that SA hit piece is made to look really foolish!!!
The writer of today's SA hit piece admits he's Short and many fell for it and gave up your position. He tricked you! Stop being fooled by the games Shorts play to stop a move by a company they're Short in.
Shorts are hiding under their beds!!
Amazing Bid Support here
That was a fake wall folks!! Don't let them steal your shares. Go BCAP!!!
Jamen's company FB page and Twitter isn't enough for you? The news is listed on Diego Pellicer's FB page as well as the article talking about him putting Plandai on the map... https://www.facebook.com/DiegoPellicerInc
The News is also listed on his companys Twitter page... https://twitter.com/DiegoPellicerCo
Still not enough for you? How about he is quoted in the company's press release announcing the deal... you do know Plandai could be sued big time for using his name and a quote from him if he didn't, in fact, give that quote and allow it. Check the 6th paragraph in the press release... http://finance.yahoo.com/news/plandai-biotechnology-inc-acquire-license-133000149.html
If that doesn't work for you then maybe give Diego Pellicer a call.
Trust this guys words because he is spot on!! Don't get caught losing your hard earned money. Only gonna get worse folks...
Was wondering the same thing. They have been coming in than disappearing all am.
Agreed slow and steady wins the race!!
Merry Christmas!!!!!!!!!!!
I actually don't see any promoters on this one. If anyone see's any please inform the board.
His car payment is around the 5th of each month so just sit on the bid and u will get some cheapies. It worked for me and I was able to depart from this POS. Curcio prove us wrong and show the REVENUES???????? Enjoy your 5 star dining tonight at the expense of the innocent share-holders..
Agreed! Looks like Yesterday's madness woke up a seller!!
Check back in 5 years lol lol!!
Pinklinks, the main quote provider for the index, took a "catastrophic" data hit and is currently down. No broker is able to give an ETA when it will go up--but this is street wide for the exchange. As SOON as we have more--we will update.
Hearing 10am issue will be fixed!
Managed to get out of this POS today and breaking even. Good luck to all I may try to pick some up when its in the .01 range again.
Up almost 100% today. Hopefully a sign of better things to come. I still would like to see some revenues Curcio!!
Pretty pathetic that they can't even run a spell-check. It's the little things that speaks volumes. Everything just seems half assed throughout all of this madness, which usually ends in a very bad demise. Kinda shocked people are even buying this, but it could be a another ploy to sucker in new investors. If I sounds bitter its because I am!!
I agree slow and steady wins the race!!
NEW Interview with Nuvilex COO, Dr. Gerald Crabtree
NEW YORK, NY--(Marketwired - Oct 17, 2013) - Nuvilex Inc.'s, (OTCQB: NVLX) Chief Operating Officer, Dr. Gerald Crabtree sat down for an interview with Stock Market Media Group, a research and content development investor relations firm. In the interview, Dr. Crabtree covered a number of topics including the Nuvilex's restructuring, its recent acquisition of a live-cell encapsulation-based technology, the company's future pancreatic cancer clinical trials and the on-going relationship with SG Austria.
The interview can be heard at www.stockmarketmediagroup.com/media.
As part of Stock Market Media Group's CEO interview series, Dr. Crabtree discusses why it was necessary for the company to restructure its operations in order to solely focus on its work as a biotech firm. He lays out the importance of the company's recent acquisition of exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment the company will use in future clinical trials. While discussing the technology, Dr. Crabtree explains why this technology works better than other cell encapsulation treatments.
Dr. Crabtree breaks down the current pancreatic cancer drug market, and outlines Nuvilex's potential future success in it by taking a look into the numbers its technology has produced. He answered a number of questions surrounding the company's future clinical trials for the treatment of advanced, inoperable pancreatic cancer; including, responses to the steps already underway, future study sites, the protocol for the trials and SG Austria's role in those upcoming trials.
Dr. Crabtree has spent over 40 years working in the field of oncology. He played a significant role in helping Bristol-Myers Squibb bring the widely popular cancer drug Taxol® to market. Nuvilex's COO is very familiar with the process of taking a drug/treatment through clinical trials, working with the Food and Drug Administration (FDA) and getting that drug to market. Stock Market Media Group feels this interview will show Dr. Crabtree's experience, knowledge and confidence with Nuvilex's plans to engage in future clinical trials.
NEW Interview with Nuvilex COO, Dr. Gerald Crabtree
NEW YORK, NY--(Marketwired - Oct 17, 2013) - Nuvilex Inc.'s, (OTCQB: NVLX) Chief Operating Officer, Dr. Gerald Crabtree sat down for an interview with Stock Market Media Group, a research and content development investor relations firm. In the interview, Dr. Crabtree covered a number of topics including the Nuvilex's restructuring, its recent acquisition of a live-cell encapsulation-based technology, the company's future pancreatic cancer clinical trials and the on-going relationship with SG Austria.
The interview can be heard at www.stockmarketmediagroup.com/media.
As part of Stock Market Media Group's CEO interview series, Dr. Crabtree discusses why it was necessary for the company to restructure its operations in order to solely focus on its work as a biotech firm. He lays out the importance of the company's recent acquisition of exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment the company will use in future clinical trials. While discussing the technology, Dr. Crabtree explains why this technology works better than other cell encapsulation treatments.
Dr. Crabtree breaks down the current pancreatic cancer drug market, and outlines Nuvilex's potential future success in it by taking a look into the numbers its technology has produced. He answered a number of questions surrounding the company's future clinical trials for the treatment of advanced, inoperable pancreatic cancer; including, responses to the steps already underway, future study sites, the protocol for the trials and SG Austria's role in those upcoming trials.
Dr. Crabtree has spent over 40 years working in the field of oncology. He played a significant role in helping Bristol-Myers Squibb bring the widely popular cancer drug Taxol® to market. Nuvilex's COO is very familiar with the process of taking a drug/treatment through clinical trials, working with the Food and Drug Administration (FDA) and getting that drug to market. Stock Market Media Group feels this interview will show Dr. Crabtree's experience, knowledge and confidence with Nuvilex's plans to engage in future clinical trials.
Curcio please get us some decent bid support and where are the promised rev's??
Thought this was about to collapse! Curious if the buying is just people trying to average down. Show us some Rev's Curcio!!
This is a POS!!
PROT up 30% weeeeeeeeeee lol.
The discussion in here will prob go back and forth another 3 or 4 times until something actually happens. If after Sept 1st we are still discussing these same issues then we obviously have all been duped and need to put a nail in the coffin!! Cheers Congrats Heat
Who keeps selling in the .04's? With any patience one could sell in the .06's. Some people are just ridiculous.
Absolutely Love how this is trading! Once we get news could easily see .80 or above. LONG on this hidden gem!!
I love your clown comments. It keeps getting better the more you complain. LMAO you may want to delete your comments, because you really look foolish dboob..
Same here, but looks like the wait will be well worth it IMO. Something is def brewing with this and now that the PPS is this high, will result in more legit investors coming in IMO.
A little late to the party... question is who is still buying this and why.. good luck to all as i have written this off as a major loss. sick of the BS circus
CADY A PIECE OF ART!! Big players on this one... Weeeeeeeeeeeeeeeeeeeeeeeeeeee